AKBM: Strong Q4 driven by Human Health Ingredients growth and strategic focus on 2026 expansion

About this update from Aker Biomarine Asa

Q4 2025 saw 6% revenue and 66% EBITDA growth, led by a 28% surge in Human Health Ingredients, while consumer health declined 8%. Strategic focus is on maximizing Human Health Ingredients value, with strong guidance for 2026 and ongoing capacity expansion.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Aker Biomarine Asa